Pediatric clinical research

Current Opinion in Rheumatology

Volumn 17, Issue 3, 2005, Pages 265-270

  Lovell, Daniel J ^a   Ruth, Natasha M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Juvenile dermatomyositis; Juvenile idiopathic arthritis; Juvenile rheumatoid arthritis; Pediatrics; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; INSULIN; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; NITRIC OXIDE; PROTEIN S 100; PROTEIN S 100 A12; PROTEIN S 100 A8; PROTEIN S 100 A9; TACROLIMUS; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; DISEASE ACTIVITY; DRUG RESPONSE; HUMAN; INSULIN BLOOD LEVEL; JUVENILE RHEUMATOID ARTHRITIS; MUSCLE MASS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; RECURRENCE RISK; RELAPSE; REVIEW; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ARTHRITIS, JUVENILE RHEUMATOID; BIOMEDICAL RESEARCH; CHILD; DERMATOMYOSITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEDIATRICS;

EID: 18144379829     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000159925.35138.6c     Document Type: Review

References (21)

1. Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzales J, et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 2004; 50:160-165. This study showed that SLE patients have higher plasma insulin levels and increased LDL oxidizability than do healthy control individuals.
2. Soep JB, Mietus-Snyder M, Malloy MJ, et al. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum 2004; 51:451-457. The authors concluded that cSLE demonstrated abnormalities in several known factors related to increased risk for atherosclerosis.
3. Ruperto N, Buratti S, Duarte-Salazar C, et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Rheum 2004; 51:458-464. Patients with cSLE had significant impairment of their HRQL, particularly in the physical domain.
4. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001. J Rheumatol 2004; 31.
5. zur Wiesch AS, Foell D, Frosch M, et al. Myeloid related proteins MRP8/ MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004; 22:368-373. MRP8/MRP14 correlates highly with clinical measures of disease activity in patients with JIA and demonstrates very good sensitivity and specificity for predicting disease flares in these patients.
6. Foell D, Wittkowski H, Hammerschmidt I, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by 3100A12 serum concentrations. Arthritis Rheum 2004; 50:1286-1295. S100A12 serum concentrations indicate neutrophil activation in juvenile RA and correlate with disease activity.
7. Knight AC, Dardzinski BJ, Laor T, et al. Magnetic resonance imaging evaluation of the effects of juvenile rheumatoid arthritis on distal femoral weight-bearing cartilage. Arthritis Rheum 2004; 50:901-905. T2 relaxation time mapping may allow for early detection of cartilage changes and provide an objective, quantitative method of monitoring disease progression, with long-term potential to guide therapy.
8. Roth J, Palm C, Scheunemann I, et al. Musculoskeletal abnormalities of the forearm in patients with juvenile idiopathic arthritis relate mainly to bone geometry. Arthritis Rheum 2004; 50:1277-1285.
9. Foell D, Forsch M, zur Wiesch AS, et al. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis 2004; 63:206-208. Longer duration of MTX treatment after induction of inactive disease during therapy does not increase the likelihood that inactive disease will continue after MTX is discontinued in patients with JIA.
10. Alsufyani K, Ortiz-Alvarez O, Cabral DA, et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31:179-182. This study suggests that in patients for whom oral MTX is ineffective, because of either inefficacy or toxicity, the use of subcutaneous MTX has a high likelihood of success.
11. Moroldo MB, Chaudhari M, Shear E, et al. Juvenile rheumatoid arthritis affected sibpairs. Arthritis Rheum 2004; 50:1928-1934.
12. Thompson SD, Moroldo MB, Guyer L, et al. A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum 2004; 50:2920-2930. This study supports the hypothesis that multiple genes, including at least one in the HLA region, influence susceptibility to juvenile RA.
13. Shaw K, Southwood TR, McDonagh JE. On behalf of the British Paediatric Rheumatology Group. Developing a programme of transitional care for adolescents with juvenile idiopathic arthritis: results of a postal survey. Rheumatology 2004; 43:211-219.
14. Shaw K, Southwood TR, McDonagh JE. On behalf of the British Paediatric Rheumatology Group. User perspectives of transitional care for adolescents with juvenile idiopathic arthritis. Rheumatology 2004; 43:770-778.
15. Shaw K, Southwood TR, McDonagh JE. On behalf of the British Paediatric Rheumatology Group. Transitional care for adolescents with juvenile idiopathic arthritis: a Delphi study. Rheumatology 2004; 43:1000-1006.
16. Malleson PN, Oen K, Cabral DA, et al. Predictors of pain in children with established juvenile rheumatoid arthritis. Arthritis Rheum 2004; 51:222-227.
17. Brunner HI, Klein-Gilelman MS, Miller MJ, et al. Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reporting. Arthritis Rheum 2004; 51:763-773.
18. Maillord S, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 2004; 43:603-608. The MRI T2 relaxation time can be used as a quantitative measure of muscle inflammation and correlates highly with other measures of disease activity.
19. Li CK, Varsani H, Holton JL, et al. MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31:605-609.
20. Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis: a review of efficacy and safety. Rheumatology 2004; 43:491-496. In this cohort of children with severe and refractory JDM, cytoxan seemed to provide major clinical benefit with no evidence of serious short-term toxicity.
21. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004; 15:35-39.